Rituximab in juvenile myasthenia gravis-an international cohort study and literature review.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Ramdas, SitharaDella Marina, Adela
Ryan, Monique M
McWilliam, Kenneth
Klein, Andrea
Jacquier, David
Alabaf, Setareh
Childs, Anne-Marie
Parasuraman, Deepak
Beeson, David
Palace, Jacqueline
Jungbluth, Heinz
Publication date
2022-06-25Subject
Neurology
Metadata
Show full item recordAbstract
Juvenile myasthenia gravis (JMG) is a rare, antibody-mediated disorder of the neuromuscular junction. Treatment strategies in JMG are largely informed by adult MG treatments as the pathophysiology is similar. Rituximab is increasingly considered as a treatment option in refractory JMG but has not yet been systematically investigated in this patient group We conducted a retrospective study from five international centres with expertise in paediatric myasthenia. 10 JMG patients treated with rituximab were identified. Following rituximab treatment all patients had a reduction in JMG-related hospital admissions. At 24 month follow up, 6 patients (60%) had achieved complete stable remission or pharmacological remission and 7 patients were able to reduce immunomodulatory treatment(s). The main side-effect was infusion-related reactions (30%) which resolved in all patients with symptomatic treatment. We compared our cohort to previously reported JMG cases treated with rituximab and noted similar response rates but a slightly higher side-effect profile. Rituximab is a safe and effective treatment option in moderate to severe JMG and most patients have an improvement in MG symptoms post treatment.Citation
Ramdas S, Della Marina A, Ryan MM, McWilliam K, Klein A, Jacquier D, Alabaf S, Childs AM, Parasuraman D, Beeson D, Palace J, Jungbluth H. Rituximab in juvenile myasthenia gravis-an international cohort study and literature review. Eur J Paediatr Neurol. 2022 Sep;40:5-10. doi: 10.1016/j.ejpn.2022.06.009. Epub 2022 Jun 25Type
ArticleAdditional Links
http://www.sciencedirect.com/science/journal/10903798PMID
35835035Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.ejpn.2022.06.009